Table 4Clinical evidence profile: risk prediction tools for the prediction of mortality in adults receiving iodine-based contrast media

Risk toolNo of studiesnRisk of biasInconsistencyIndirectnessImprecisionMean effect size (95% CI)GRADE overall quality
Mehran risk score1891High1NAHigh2High3AUC= 0.74 (0.59-0.79)VERY LOW
Mehran risk score (medium risk) vs low risk1891High1NAHigh2LowHR= 3.61 (2.19-5.98)LOW
Mehran risk score (high risk) vs low risk1891High1NAHigh2LowHR= 8.00 (4.53-14.13)LOW
Mehran risk score (very high risk) vs low risk1891High1NAHigh2LowHR= 15.29 (8.11-28.83)LOW
Marenzi risk score1891High1NAHigh2LowAUC= 0.60 (0.55-0.65)LOW
GRACE score (<136)1251Very high4NANot seriousLowSensitivity= 0% (0-31)LOW
Very high4NANot seriousLowSpecificity= 75% (69-80)LOW
GRACE score (136-158)1251Very high4NANot seriousLowSensitivity= 20% (3-56)LOW
Very high4NANot seriousLowSpecificity= 75% (69-80)LOW
GRACE score (159-180)1251Very high4NANot seriousLowSensitivity= 20% (3-56)LOW
Very high4NANot seriousLowSpecificity= 74% (68-80)LOW
GRACE score (>180)1251Very high4NANot seriousVery serious5Sensitivity= 60% (26-88)VERY LOW
Very high4NANot seriousSerious6Specificity= 76% (70-82)VERY LOW
1

Downgraded by one increment due to very high risk of bias arising from the PROBAST risk of bias tool, namely due to unclear timing of the assessment of predictors relative to outcome assessment and concerns arising from the analysis method (discrimination reported without calibration)

2

Downgraded by one increment due to high levels of concern surrounding the applicability of the risk prediction tool (not all predictors available at the intended time of assessment (prior to contrast administration))

3

Downgraded by one increment due to the 95%CI overlapping the upper threshold for decision making (0.70)

4

Downgraded by two increments due to very high risk of bias arising from multiple domains of the PROBAST risk of bias tool, namely due to unclear definitions and assessments of predictors (timing and criteria not specified), inadequate sample size (<100 events) and incomplete analysis reporting (discrimination reported without calibration)

5

Downgraded by two increments due to the 95%CI overlapping both the threshold corresponding to ‘low sensitivity’ (60%) and ‘high sensitivity’ (80%)

6

Downgraded by one increment due to the 95%CI overlapping the threshold corresponding to ‘low specificity’ (80%)

From: Evidence review for risk prediction tools and eGFR for the prediction of iodine-based contrast media-associated acute kidney injury

Cover of Evidence review for risk prediction tools and eGFR for the prediction of iodine-based contrast media-associated acute kidney injury
Evidence review for risk prediction tools and eGFR for the prediction of iodine-based contrast media-associated acute kidney injury: Acute Kidney Injury (update): Evidence review B.
NICE Guideline, No. 148.
Copyright © NICE 2024.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.